NextCure doses first patient in Phase 1 study of B7-H4 ADC LNCB74 for multiple cancers

NextCure, Inc.

First patient dosed in Phase 1 study of LNCB74, a B7-H4-targeting ADC.
LNCB74 is being developed as a therapeutic for treating multiple cancers.
FDA cleared the IND for LNCB74 in December 2024.
LNCB74 is developed in partnership with LigaChem Biosciences.
Phase 1 aims to evaluate safety, tolerability, and preliminary anti-tumor activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.